Interrogating open issues in cancer precision medicine with patient-derived xenografts

EurOPDX Consortium; Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino

doi:10.1038/nrc.2016.140

Interrogating open issues in cancer precision medicine with patient-derived xenografts

EurOPDX Consortium, Annette T Byrne, Denis G Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K Chang, Robert B Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S Gail Eckhardt, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika A JarzabekSteven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G Palmer, Daniel S Peeper, Pier Giuseppe Pelicci, Alejandro Piris-Gimenez, Sergio Roman-Roman, Oscar M Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti, Livio Trusolino

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Commentary/debate › peer-review

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

Original language	English
Journal	Nature Reviews. Cancer
Early online date	20 Jan 2017
DOIs	https://doi.org/10.1038/nrc.2016.140
Publication status	Published - 2017

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrc.2016.140

Cite this

EurOPDX Consortium, Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G., Gonzalez-Suarez, E., Hermans, E., Hidalgo, M., ... Trusolino, L. (2017). Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews. Cancer. https://doi.org/10.1038/nrc.2016.140

@article{cf0de03743c44c1fbc9b84b1b7fc3418,

title = "Interrogating open issues in cancer precision medicine with patient-derived xenografts",

abstract = "Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.",

author = "{EurOPDX Consortium} and Byrne, {Annette T} and Alf{\'e}rez, {Denis G} and Fr{\'e}d{\'e}ric Amant and Daniela Annibali and Joaqu{\'i}n Arribas and Biankin, {Andrew V} and Alejandra Bruna and Eva Budinsk{\'a} and Carlos Caldas and Chang, {David K} and Clarke, {Robert B} and Hans Clevers and George Coukos and Virginie Dangles-Marie and Eckhardt, {S Gail} and Eva Gonzalez-Suarez and Els Hermans and Manuel Hidalgo and Jarzabek, {Monika A} and {de Jong}, Steven and Jos Jonkers and Kristel Kemper and Luisa Lanfrancone and M{\ae}landsmo, {Gunhild Mari} and Elisabetta Marangoni and Jean-Christophe Marine and Enzo Medico and Norum, {Jens Henrik} and Palmer, {H{\'e}ctor G} and Peeper, {Daniel S} and Pelicci, {Pier Giuseppe} and Alejandro Piris-Gimenez and Sergio Roman-Roman and Rueda, {Oscar M} and Joan Seoane and Violeta Serra and Laura Soucek and Dominique Vanhecke and Alberto Villanueva and Emilie Vinolo and Andrea Bertotti and Livio Trusolino",

year = "2017",

doi = "10.1038/nrc.2016.140",

language = "English",

journal = "Nature Reviews. Cancer",

issn = "1474-1768",

publisher = "Springer Nature",

}

EurOPDX Consortium, Byrne, AT, Alférez, DG, Amant, F, Annibali, D, Arribas, J, Biankin, AV, Bruna, A, Budinská, E, Caldas, C, Chang, DK, Clarke, RB, Clevers, H, Coukos, G, Dangles-Marie, V, Eckhardt, SG, Gonzalez-Suarez, E, Hermans, E, Hidalgo, M, Jarzabek, MA, de Jong, S, Jonkers, J, Kemper, K, Lanfrancone, L, Mælandsmo, GM, Marangoni, E, Marine, J-C, Medico, E, Norum, JH, Palmer, HG, Peeper, DS, Pelicci, PG, Piris-Gimenez, A, Roman-Roman, S, Rueda, OM, Seoane, J, Serra, V, Soucek, L, Vanhecke, D, Villanueva, A, Vinolo, E, Bertotti, A & Trusolino, L 2017, 'Interrogating open issues in cancer precision medicine with patient-derived xenografts', Nature Reviews. Cancer. https://doi.org/10.1038/nrc.2016.140

TY - JOUR

T1 - Interrogating open issues in cancer precision medicine with patient-derived xenografts

AU - EurOPDX Consortium

AU - Byrne, Annette T

AU - Alférez, Denis G

AU - Amant, Frédéric

AU - Annibali, Daniela

AU - Arribas, Joaquín

AU - Biankin, Andrew V

AU - Bruna, Alejandra

AU - Budinská, Eva

AU - Caldas, Carlos

AU - Chang, David K

AU - Clarke, Robert B

AU - Clevers, Hans

AU - Coukos, George

AU - Dangles-Marie, Virginie

AU - Eckhardt, S Gail

AU - Gonzalez-Suarez, Eva

AU - Hermans, Els

AU - Hidalgo, Manuel

AU - Jarzabek, Monika A

AU - de Jong, Steven

AU - Jonkers, Jos

AU - Kemper, Kristel

AU - Lanfrancone, Luisa

AU - Mælandsmo, Gunhild Mari

AU - Marangoni, Elisabetta

AU - Marine, Jean-Christophe

AU - Medico, Enzo

AU - Norum, Jens Henrik

AU - Palmer, Héctor G

AU - Peeper, Daniel S

AU - Pelicci, Pier Giuseppe

AU - Piris-Gimenez, Alejandro

AU - Roman-Roman, Sergio

AU - Rueda, Oscar M

AU - Seoane, Joan

AU - Serra, Violeta

AU - Soucek, Laura

AU - Vanhecke, Dominique

AU - Villanueva, Alberto

AU - Vinolo, Emilie

AU - Bertotti, Andrea

AU - Trusolino, Livio

PY - 2017

Y1 - 2017

N2 - Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

AB - Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

U2 - 10.1038/nrc.2016.140

DO - 10.1038/nrc.2016.140

M3 - Commentary/debate

C2 - 28104906

SN - 1474-1768

JO - Nature Reviews. Cancer

JF - Nature Reviews. Cancer

ER -

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this